AP2015008801A0 - Methods for treating crohn's disease using an anti-il23 antibody - Google Patents

Methods for treating crohn's disease using an anti-il23 antibody

Info

Publication number
AP2015008801A0
AP2015008801A0 AP2015008801A AP2015008801A AP2015008801A0 AP 2015008801 A0 AP2015008801 A0 AP 2015008801A0 AP 2015008801 A AP2015008801 A AP 2015008801A AP 2015008801 A AP2015008801 A AP 2015008801A AP 2015008801 A0 AP2015008801 A0 AP 2015008801A0
Authority
AP
ARIPO
Prior art keywords
antibody
disease
methods
treating crohn
crohn
Prior art date
Application number
AP2015008801A
Other languages
English (en)
Inventor
Wayne Tsuji
Wei-Jian Pan
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of AP2015008801A0 publication Critical patent/AP2015008801A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
AP2015008801A 2013-03-15 2014-02-25 Methods for treating crohn's disease using an anti-il23 antibody AP2015008801A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361789976P 2013-03-15 2013-03-15
PCT/US2014/018308 WO2014143540A1 (en) 2013-03-15 2014-02-25 Methods for treating crohn's disease using an anti-il23 antibody

Publications (1)

Publication Number Publication Date
AP2015008801A0 true AP2015008801A0 (en) 2015-10-31

Family

ID=50236361

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2015008801A AP2015008801A0 (en) 2013-03-15 2014-02-25 Methods for treating crohn's disease using an anti-il23 antibody

Country Status (17)

Country Link
US (5) US20160031983A1 (zh)
EP (2) EP2968486A1 (zh)
JP (4) JP2016516686A (zh)
KR (1) KR20150128859A (zh)
CN (1) CN105307675A (zh)
AP (1) AP2015008801A0 (zh)
AU (1) AU2014228553B2 (zh)
CA (1) CA2906384A1 (zh)
CL (1) CL2015002724A1 (zh)
EA (1) EA201591579A1 (zh)
HK (1) HK1220605A1 (zh)
IL (2) IL241343A0 (zh)
NZ (1) NZ712294A (zh)
PH (1) PH12015502133A1 (zh)
SG (2) SG11201507483PA (zh)
TN (1) TN2015000402A1 (zh)
WO (1) WO2014143540A1 (zh)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103282382B (zh) 2010-11-04 2017-11-03 勃林格殷格翰国际有限公司 抗il‑23抗体
KR102124758B1 (ko) 2012-05-03 2020-06-19 베링거 인겔하임 인터내셔날 게엠베하 항-ｉｌ-23ｐ19 항체
JP2017524359A (ja) 2014-07-24 2017-08-31 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｉｌ−２３ａ関連疾患の処置に有用なバイオマーカー
EA202193002A2 (ru) 2014-09-03 2022-03-31 Бёрингер Ингельхайм Интернациональ Гмбх Соединение, нацеленное на ил-23a и фно-альфа, и его применение
AR102417A1 (es) 2014-11-05 2017-03-01 Lilly Co Eli Anticuerpos biespecíficos anti-tnf- / anti-il-23
EP3262072A1 (en) * 2015-02-26 2018-01-03 F. Hoffmann-La Roche AG Integrin beta7 antagonists and methods of treating crohn's disease
TWI733695B (zh) * 2015-09-18 2021-07-21 德商百靈佳殷格翰國際股份有限公司 治療發炎性疾病之方法
AU2017241776A1 (en) * 2016-03-29 2018-10-11 Janssen Biotech, Inc. Treating psoriasis with increased interval dosing of anti-IL12 and/or -23 antibody
EP3677597A1 (en) * 2016-10-14 2020-07-08 Boehringer Ingelheim International GmbH Methods of treating diseases
AU2019300491A1 (en) * 2018-07-13 2021-03-04 Astrazeneca Collaboration Ventures, Llc Treating ulcerative colitis with brazikumab
TW202103734A (zh) 2019-04-22 2021-02-01 美商美國禮來大藥廠 治療克隆氏症（ｃｒｏｈｎ＇ｓ ｄｉｓｅａｓｅ）的方法
TW202120545A (zh) * 2019-08-21 2021-06-01 美商阿斯特捷利康合作創業有限責任公司 布拉奇單抗用於治療克羅恩氏病的用途
CN111956606B (zh) * 2020-08-31 2021-05-14 江苏荃信生物医药有限公司 包含高浓度抗人白介素23单克隆抗体的低粘度液体制剂

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
CO4810232A1 (es) 1997-07-25 1999-06-30 Schering Corp Citoquinas de mamiferos y sus secuencias codificadoras
EP1896073B1 (en) 2005-06-30 2013-03-06 Janssen Biotech, Inc. Anti-il-23 antibodies, compositions, methods and uses
MX2008002179A (es) 2005-08-25 2008-04-22 Lilly Co Eli Anticuerpos anti-il-23.
US20070050011A1 (en) 2005-08-26 2007-03-01 Medlogics Device Corporation Lumen-supporting stents and methods for creating lumen-supporting stents with various open/closed designs
ES2619845T3 (es) 2005-08-31 2017-06-27 Merck Sharp & Dohme Corp. Anticuerpos anti-IL-23 diseñados por ingeniería genética
US7686047B2 (en) * 2005-11-04 2010-03-30 Roger Cleveland Golf Co., Inc. Golf club cover
ES2517420T3 (es) * 2005-12-29 2014-11-03 Janssen Biotech, Inc. Anticuerpos anti-IL-23 humanos, composiciones, procedimientos y usos
WO2007147019A2 (en) 2006-06-13 2007-12-21 Zymogenetics, Inc. Il-17 and il-23 antagonists and methods of using the same
HUE042172T2 (hu) 2007-02-23 2019-06-28 Merck Sharp & Dohme Genetikailag elõállított anti-il-23P19 antitestek
CN103396489A (zh) * 2007-02-23 2013-11-20 默沙东公司 工程改造的抗IL-23p19抗体
AR068723A1 (es) 2007-10-05 2009-12-02 Glaxo Group Ltd Proteina que se une a antigenos que se une a il-23 humana y sus usos
US20090117289A1 (en) * 2007-10-09 2009-05-07 Enerize Corporation Method and apparatus for deposition of thin film materials for energy storage devices
WO2009082624A2 (en) 2007-12-10 2009-07-02 Zymogenetics, Inc. Antagonists of il-17a, il-17f, and il-23 and methods of using the same
TW201513883A (zh) * 2008-03-18 2015-04-16 Abbvie Inc 治療牛皮癬的方法
US8263748B2 (en) 2008-08-27 2012-09-11 Schering Corporation Lyophilized formulations of engineered anti-IL-23p19 antibodies
EP2414393A1 (en) 2009-04-01 2012-02-08 Glaxo Group Limited Anti-il-23 immunoglobulins
US20120264917A1 (en) 2009-05-27 2012-10-18 Ablynx N.V. Biparatopic protein constructs directed against il-23
JO3244B1 (ar) * 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
SG10201604093XA (en) 2010-01-15 2016-07-28 Kirin Amgen Inc Antibody formulation and therapeutic regimens
US9127057B2 (en) 2010-07-20 2015-09-08 Teva Pharmaceuticals Ausralia Pty Ltd Anti-IL-23 heterodimer specific antibodies
CN103154031A (zh) * 2010-10-08 2013-06-12 诺华有限公司 利用il-17拮抗剂治疗牛皮癣的方法
CN103282382B (zh) 2010-11-04 2017-11-03 勃林格殷格翰国际有限公司 抗il‑23抗体
JP2014506132A (ja) * 2011-01-07 2014-03-13 アッヴィ・インコーポレイテッド 抗ｉｌ−１２／ｉｌ−２３抗体およびその使用

Also Published As

Publication number Publication date
KR20150128859A (ko) 2015-11-18
US20200283517A1 (en) 2020-09-10
EP3693007A1 (en) 2020-08-12
EA201591579A1 (ru) 2016-01-29
US20180327490A1 (en) 2018-11-15
EP2968486A1 (en) 2016-01-20
US20200017581A1 (en) 2020-01-16
AU2014228553A1 (en) 2015-10-08
PH12015502133A1 (en) 2016-01-25
CA2906384A1 (en) 2014-09-18
JP2016516686A (ja) 2016-06-09
US20160031983A1 (en) 2016-02-04
CN105307675A (zh) 2016-02-03
JP2021107397A (ja) 2021-07-29
NZ712294A (en) 2020-04-24
HK1220605A1 (zh) 2017-05-12
JP2023012516A (ja) 2023-01-25
US20170218062A1 (en) 2017-08-03
IL275092A (en) 2020-07-30
IL241343A0 (en) 2015-11-30
TN2015000402A1 (fr) 2017-01-03
AU2014228553B2 (en) 2019-01-24
WO2014143540A1 (en) 2014-09-18
SG11201507483PA (en) 2015-10-29
JP2020073470A (ja) 2020-05-14
CL2015002724A1 (es) 2016-03-28
SG10201805015TA (en) 2018-07-30

Similar Documents

Publication Publication Date Title
IL275092A (en) Methods for treating Crohn's disease using an anti-IL-23 antibody
IL292193A (en) Anti-b7–h1 antibodies for the treatment of tumors
TWI563003B (en) Human anti-il-33 neutralization monoclonal antibody
IL245196B (en) Antibodies against cd38 for the treatment of human cancers
HK1212710A1 (zh) 用於選擇針對 的抗體的方法
ZA201504861B (en) Apparatus for improved disease detection
HK1219958A1 (zh) 抗體
HK1215373A1 (zh) 用於治療代謝疾病的方法和裝置
IL244042A0 (en) A method for treating leiftic disease
EP2849785A4 (en) METHOD FOR THE TREATMENT OF CANCER WITH NOTCH2 / 3 ANTIBODIES
EP2978446A4 (en) METHODS AND AGENTS FOR THE TREATMENT OF ALZHEIMER'S DISEASE
EP3024482A4 (en) Methods for diagnosing and treating immune disease
EP2959903A4 (en) MEDICAMENT FOR THE TREATMENT OF EYE DRESSING
HK1217910A1 (zh) 骨用生物特異性試劑
HK1219961A1 (zh) 人抗α型干擾素抗體
EP2968452A4 (en) COMPOSITIONS AND METHOD FOR THE TREATMENT OF NETWORK DISEASES
IL252904A0 (en) Methods and factors for treating diseases
GB201312226D0 (en) Improved antibodies
PL3016977T3 (pl) Ludzkie przeciwciała anty-IL-32
EP2947462A4 (en) SAMPLE PROCESSING SYSTEM
GB201309509D0 (en) Diagnostic marker for crohn's disease
GB201302884D0 (en) Novel methods for diagnosis and therapy